BANK VONTOBEL/PUT/BIOGEN IDEC/210/0.01/20.09.24 | Market Closed - Deutsche Boerse AG 01:41:51 2024-07-16 pm EDT | ||
| 0.064 EUR | -1.54% |
|
| Current month | +38.30% | ||
| 1 month | +35.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.064 | -1.54% |
| 24-07-15 | 0.065 | +30.00% |
| 24-07-12 | 0.05 | +42.86% |
| 24-07-11 | 0.035 | -16.67% |
| 24-07-10 | 0.042 | -12.50% |
Delayed Quote Deutsche Boerse AG
Last update July 16, 2024 at 01:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VM3MH8 |
| ISIN | DE000VM3MH83 |
| Date issued | 2023-10-06 |
| Strike | 210 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 100 : 1 |
| Emission price | 0.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.25 € |
|---|---|
| Lowest since issue | 0.033 € |
| Spread | 0.01 € |
| Spread % | 13.89% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
221.6
USD
Average target price
281.2
USD
Spread / Average Target
+26.90%
- Stock Market
- Warrants
- Warrant
